A phase 1 trial of siRNA Therapeutic
Latest Information Update: 16 May 2025
At a glance
- Drugs SLN 312 (Primary)
- Indications Unspecified
- Focus Adverse reactions
Most Recent Events
- 08 May 2025 According to a Silence Therapeutics media release, in this phase 1 study of SLN312, (licensed to AstraZeneca) collaboration is ongoing.
- 29 Feb 2024 New trial record
- 26 Feb 2024 According to a Silence Therapeutics media release, company announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.